Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer

Lung Cancer

Volumn 16, Issue 1, 1996, Pages 75-80

  Salomaa, Eija Riitta ^a   Liippo, Kari ^a   Ellmen, Juha ^b   Komi, Janne ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

chemotherapy; ifosfamide; multi drug resistance; non small cell lung cancer; toremifene

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE; TOREMIFENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031040099     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(96)00613-7     Document Type: Article

References (10)

1. [1] Agresti A. Categorial data analysis. John Wiley and Sons, New York, 1990.
2. [2] Baker WJ, Wiebe V, Koester S et al. Toremifene enhances doxorubicin accumulation, inhibits protein kinase C (PKC) acitivity, increses PKC message and enhances cytotoxicity in a tumour-bearing multidrug-resistant nude mouse model. Proc Am Soc Clin Oncol 1992; 11: 109.
3. [3] DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. Toremifene: pharmacological and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 1989; 7: 1359-1364.
4. [4] Ettinger DS. Ifosfamide in the treatment of non-small cell lung cancer. Semin Oncol 1989; 16: (suppl 3), 3-38.
5. [5] Kangas L. Alcylating effect of toremifene. Research report 11 August 1982. Orion Corporation.
6. [6] Mäenpää J, Sipilä P, Kangas L, Karnani P, Grönroos M. Chemosensitizing effect of an antiestrogen, toremifene on ovarian cancer. Gynecol Oncol 1992; 46: 292-297.
7. [7] Ozols RF, Hamilton TC, Fojo AT, Lai GM, Rothenberg M, Young CC. Reversal of alkylating agent and platinum resistance in ovarian cancer. Proc Annu Meet Am Assoc Cancer Res 1988; 29: 526-527.
8. [8] Shin HJ, Lee JS, Hong WK, Shin DM. Study of multidrug resistance (MDR-1) gene in non-small cell lung cancer. Anticancer Res 1992; 12: 367-370.
9. [9] Virtanen R. Analgesic effect of toremifene. Research report 3 February 1986. Orion Corporation.
10. [10] Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ. Targeting chemosensitising doses of toremifene based on protein binding. Cancer Chemother Pharmacol 1992; 31: 412-414.